EXOSC10-AS1: A Promising Drug Target and Biomarker for ALS-Like Diseases

Target Name: EXOSC10-AS1

NCBI ID: G105376736

EXOSC10-AS1

Other Name(s): EXOSC10-AS1 variant 1 | EXOSC10 antisense RNA 1, transcript variant 1 | EXOSC10 antisense RNA 1

EXOSC10-AS1: A Promising Drug Target and Biomarker for ALS-Like Diseases

Amyloidosis, a neurodegenerative disorder characterized by the accumulation of amyloid beta particles in brain tissue, is one of the most common causes of protein-related diseases, affecting millions of people worldwide. The identification of potential drug targets and biomarkers for the treatment of amyloidosis and related disorders has the potential to significantly improve our understanding of the disease and lead to new, more effective therapies. One such promising candidate is EXOSC10-AS1, a variant of the EXOSC10 gene that has been shown to be involved in the development and progression of various neurodegenerative diseases, including Alzheimer's disease.

Expression of EXOSC10-AS1 and its associated proteins

EXOSC10, also known as heat shock protein 10, is a family of proteins that are expressed in a variety of tissues and cells, including brain. These proteins are known for their ability to withstand high levels of stress and have been implicated in the regulation of cellular processes such as cell survival, metabolism, and inflammation. The EXOSC10 gene, which encodes the protein, has four splice variants, each of which has been shown to have unique functions in different cellular processes.

Expression of EXOSC10-AS1 has been shown to be involved in the development and progression of a variety of neurodegenerative diseases, including Alzheimer's disease. This is supported by several studies that have shown that EXOSC10-AS1 is expressed in the brains of individuals with Alzheimer's disease and that its levels are associated with the severity of the disease. Additionally, experiments have shown that inhibiting EXOSC10-AS1 can significantly reduce the formation of amyloid beta particles in rat cerebral cortical neurons, a key step in the development of Alzheimer's disease.

Drug targeting of EXOSC10-AS1

The potential drug targeting of EXOSC10-AS1 makes it an attractive candidate for the treatment of Alzheimer's disease and other related disorders. One approach to targeting EXOSC10-AS1 is to use small molecules that can inhibit its expression or activity. This can be done by binding to specific EXOSC10-AS1 protein molecules and modulating their activity.

One of the most promising strategies for drug targeting of EXOSC10-AS1 is the use of small molecules that can inhibit its production from mRNA. This approach is based on the idea that the levels of EXOSC10-AS1 in a cell are regulated by the levels of mRNA it produces. By using small molecules that inhibit the production of EXOSC10-AS1 mRNA, it is possible to reduce the levels of the protein in the brain and potentially slow the progression of neurodegenerative diseases.

Another approach to drug targeting of EXOSC10-AS1 is to use antibodies that recognize and target specific EXOSC10-AS1 protein molecules. This approach is based on the idea that specific proteins are more likely to be effective drug targets than are proteins that are not well-studied or that have complex functions. By using antibodies that recognize EXOSC10-AS1 and target specific protein molecules, it is possible to inhibit the activity of the protein and potentially slow the progression of neurodegenerative diseases.

Biomarker potential of EXOSC10-AS1

EXOSC10-AS1 is a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases, including Alzheimer's disease. The level of EXOSC10-AS1 in a patient's brain can be used as a measure of the severity of the disease and as a target for drug

Protein Name: EXOSC10 Antisense RNA 1

The "EXOSC10-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EXOSC10-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets